EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access

Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study

Aditya Bardia iD, Ian E Krop iD, Takahiro Kogawa iD, Dejan Juric iD, Anthony W Tolcher iD, Erika P Hamilton iD, Toru Mukohara iD, Aaron Lisberg iD, Toshio Shimizu iD, Alexander I Spira iD, Junji Tsurutani iD, Senthil Damodaran iD und 8 weitere

Journal of Clinical Oncology · 01.07.2024 · 42 (19) · 2281-2294

DOI: 10.1200/jco.23.01909 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.07.2024. Verfasst von Aditya Bardia und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Immunoconjugates, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Datopotamab deruxtecan (Dato-DXd) is an antibody-drug conjugate consisting of a humanized antitrophoblast cell-surface antigen 2 (TROP2) monoclonal antibody linked to a potent, exatecan-derived topoisomerase I inhibitor payload via a plasma-stable, selectively cleavable linker. PATIENTS AND METHODS TROPION-PanTumor01 (ClinicalTrials.gov identifier: NCT03401385 ) is a phase I, dose-escalation, and dose-expansion study evaluating Dato-DXd in patients with previously treated solid tumors. The primary study objective was to assess the safety and tolerability of Dato-DXd. Secondary objectives included evaluation of antitumor activity and pharmacokinetics. Results from patients with advanced/metastatic hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer (BC) or triple-negative BC (TNBC) are reported. RESULTS At data cutoff (July 22, 2022), 85 patients (HR+/HER2– BC = 41, and TNBC = 44) had received Dato-DXd. The objective response rate by blinded independent central review was 26.8% (95% CI, 14.2 to 42.9) and 31.8% (95% CI, 18.6 to 47.6) for patients with HR+/HER2– BC and TNBC, respectively. The median duration of response was not evaluable in the HR+/HER2– BC cohort and 16.8 months in the TNBC cohort. The median progression-free survival in patients with HR+/HER2– BC and TNBC was 8.3 and 4.4 months, respectively. All-cause treatment-emergent adverse events (TEAEs; any grade, grade ≥3) were observed in 100% and 41.5% of patients with HR+/HER2– BC and 100% and 52.3% of patients with TNBC. Stomatitis was the most common TEAE (any grade, grade ≥3) in both HR+/HER2– BC (82.9%, 9.8%) and TNBC (72.7%, 11.4%) cohorts. CONCLUSION In patients with heavily pretreated advanced HR+/HER2– BC and TNBC, Dato-DXd demonstrated promising clinical activity and a manageable safety profile. Dato-DXd is currently being evaluated in phase III studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesHumansFemaleMiddle AgedAgedAdultCamptothecinReceptors, EstrogenAntibodies, Monoclonal, HumanizedReceptors, ProgesteroneAntigens, NeoplasmCell Adhesion MoleculesTrastuzumab

Substanzen

ImmunoconjugatesErb-b2 Receptor Tyrosine KinasesCamptothecinReceptors, EstrogenAntibodies, Monoclonal, HumanizedReceptors, ProgesteroneAntigens, NeoplasmCell Adhesion MoleculesTrastuzumabERBB2 protein, human

Autor:innen und Institutionen

  • Department of Medicine, Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA.
  • Yale Cancer Center, New Haven, CT.
  • Dana-Farber Cancer Institute, Boston, MA.
  • Department of Advanced Medical Development, Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • South Texas Accelerated Research Therapeutics, San Antonio, TX.
  • NEXT Oncology, San Antonio, TX.

ORCID-Profile: Aditya Bardia, Ian E Krop, Takahiro Kogawa, Dejan Juric, Anthony W Tolcher, Erika P Hamilton, Toru Mukohara, Aaron Lisberg, Toshio Shimizu, Alexander I Spira, Junji Tsurutani, Senthil Damodaran, Kyriakos P Papadopoulos, Funda Meric-Bernstam

Förderung

  • NCI NIH HHS

Zitieren

APA

Bardia, A., Krop, I. E., Kogawa, T., Juric, D., Tolcher, A. W., Hamilton, E. P., Mukohara, T., Lisberg, A., Shimizu, T., Spira, A. I., Tsurutani, J., Damodaran, S., Papadopoulos, K. P., Greenberg, J., Kobayashi, F., Zebger-Gong, H., Wong, R., Kawasaki, Y., Nakamura, T., & Meric-Bernstam, F. (2024). Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of Clinical Oncology, 42(19), 2281-2294. https://doi.org/10.1200/jco.23.01909

Vancouver

Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, et al. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. Journal of Clinical Oncology. 2024;42(19):2281-2294. doi:10.1200/jco.23.01909

BibTeX
@article{Bardia2024,
  author = {Bardia, Aditya and Krop, Ian E and Kogawa, Takahiro and Juric, Dejan and Tolcher, Anthony W and Hamilton, Erika P and Mukohara, Toru and Lisberg, Aaron and Shimizu, Toshio and Spira, Alexander I and Tsurutani, Junji and Damodaran, Senthil and Papadopoulos, Kyriakos P and Greenberg, Jonathan and Kobayashi, Fumiaki and Zebger-Gong, Hong and Wong, Rie and Kawasaki, Yui and Nakamura, Tadakatsu and Meric-Bernstam, Funda},
  title = {Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2– and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {19},
  pages = {2281--2294},
  doi = {10.1200/jco.23.01909}
}
Kostenlos starten →